Evgen Pharma plc (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will hold its Annual General Meeting later today in Manchester. At the AGM, the Company’s Chairman, Barry Clare, will make the following statement:
“The current financial year has seen major progress with SFX-01, our lead product candidate, which continues to progress through two Phase II trials in metastatic breast cancer and subarachnoid haemorrhage, a type of stroke.
“The final read-out from both trials continues to be expected at around the end of this calendar year, marking important value inflexion points in the clinical development of SFX-01.
“We have already announced highly encouraging data from the metastatic breast cancer trial in an interim update in June 2018, which revealed SFX-01’s signs of anti-tumour activity in a patient group where other treatment options had failed.
“Furthermore, yesterday we announced that the main aims of the metastatic breast cancer trial had been achieved, namely a favourable safety profile and evidence of clinical benefit, and that recruitment into the trial had been concluded at 50 patients rather than the total of 60 allowed under the trial protocol. We await the final details of the read-out of the trial with excitement, and see the likely next step for SFX-01 in metastatic breast cancer as a placebo-controlled trial with SFX-01 in combination with second-line hormone therapy in patients who have failed on CDK4/6 inhibitors.
“Patient recruitment continues on track in the subarachnoid haemorrhage trial with all three sites recruiting, including the most recent site addition, St Bartholomew’s Hospital, London.
“We look forward to providing further updates on both the clinical and corporate development of the Company during the months ahead.”
